- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map ; volume:23 ; number:1 ; day:14 ; month:6 ; year:2023 ; pages:1-23 ; date:12.2023
BMC cancer ; 23, Heft 1 (14.6.2023), 1-23, 12.2023
- Creator
-
Fu, Minjie
Zhou, Zhirui
Huang, Xiao
Chen, Zhenchao
Zhang, Licheng
Zhang, Jinsen
Hua, Wei
Mao, Ying
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-11043-6
- URN
-
urn:nbn:de:101:1-2023092012490592071559
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
06.11.2025, 4:56 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fu, Minjie
- Zhou, Zhirui
- Huang, Xiao
- Chen, Zhenchao
- Zhang, Licheng
- Zhang, Jinsen
- Hua, Wei
- Mao, Ying
- SpringerLink (Online service)
Other Objects (12)
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
Myoinositol as a biomarker in recurrent glioblastoma treated with bevacizumab : a 1H-magnetic resonance spectroscopy study
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)
Recurrent Glioblastoma: Where we stand
Recurrent glioblastoma: Nuances and insights
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Retraction: Recurrent Glioblastoma: Where we stand
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
Myoinositol as a biomarker in recurrent glioblastoma treated with bevacizumab : a 1H-magnetic resonance spectroscopy study
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)
Recurrent Glioblastoma: Where we stand
Recurrent glioblastoma: Nuances and insights
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Retraction: Recurrent Glioblastoma: Where we stand
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
Myoinositol as a biomarker in recurrent glioblastoma treated with bevacizumab : a 1H-magnetic resonance spectroscopy study
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)
Recurrent Glioblastoma: Where we stand
Recurrent glioblastoma: Nuances and insights
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma